Efavirenz and Ritonavir on Human Brain P-Glycoprotein

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

August 31, 2016

Conditions
Drug Effects
Interventions
DRUG

[11C] desmethyl-loperamide

IV administration of 10-14 mCi of \[11C\] desmethyl-loperamide with PET/CT imaging

OTHER

Control - no pretreatment

Session 1: IV administration of 10-14 mCi \[11C\] desmethyl-loperamide (dLop) with PET/CT imaging and brain MRI

DRUG

Oral ritonavir

Session 2: Pretreatment with oral ritonavir for 3 days followed by IV administration of 10-14 mCi \[11C\]dLop with PET/CT imaging and brain MRI

DRUG

Oral efavirenz

Session 3: Pretreatment with oral efavirenz for 14 days followed by IV administration of 10-14 mCi \[11C\]dLop with PET/CT imaging and brain MRI

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT01668147 - Efavirenz and Ritonavir on Human Brain P-Glycoprotein | Biotech Hunter | Biotech Hunter